Výsledky vyhledávání

Akademický článek

The Impact of Fibroblast Growth Factor Receptor Alterations in Clinical Outcomes of Patients With Advanced Urothelial Carcinoma: Real-World Data From a Latin American Population.

Autor: Souza VC; Oncologia D' Or Salvador, Salvador, Brazil. Electronic address: vcscarrera@gmail.com., Monteiro FSM; Hospital Universitário de Brasília (UNB), Brasília, Brazil; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Maluf FC; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Werutsky G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Fabrício VC; Janssen Latin America, Buenos Aires, Argentina., Gidekel R; Janssen Latin America, Buenos Aires, Argentina., Gandur-Quiroga MN; Instituto de Oncologia Ángel H. Roffo, Buenos Aires, Argentina., Freitas MRP; Centro de Pesquisas Oncológicas (CEPON), Florianópolis, Brazil., Luz M; 5Hospital Erasto Gaertner, Curitiba, Brazil., Campos-Gomez S; Centro Oncológico Estatal ISSEMYM, Toluca de Lerdo, Mexico., Junior JAR; A.C. Camargo, São Paulo, Brazil., Bastos DA; Hospital Sírio-Libanês, São Paulo, Brazil., Sade JP; Instituto Alexander Fleming, Buenos Aires, Argentina., da Trindade KM; IEP Oncocentro, Fortaleza, Brazil., Mota ACA; Clínica AMO - Assistência Multidisciplinar em Oncologia, Salvador, Brazil., Fernandes RC; Santa Casa de São Paulo, São Paulo, Brazil., Ruíz AOB; Clínicas Médicas Especializadas NUCARE, Ciudad de Guatemala, Guatemala., Pereira E Silva BD; Hospital São Rafael, São Paulo, Brazil., de Oliveira FNG; CLION, Salvador, Brazil., Cutuli HJ; Asociacion de Beneficencia Hospital Sirio-Libanes, Buenos Aires, Argentina., Nogueira L; Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Brazil., Aceituno LFG; Clinica Oncologica, Ciudad de Guatemala, Guatemala., Fernandez M; COIR - Fundación Centro Oncológico de Integración Regional, Mendoza, Argentina., Inman E; ONCOR, Saltillo Coahuila, Mexico., Caitano M; Centro de Oncologia do Paraná, Curitiba, Brazil., Herchenhorn D; Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Rio De Janeiro, Brazil., Ardila-Salcedo J; Janssen Latin America, Bogota, Colombia., Pacheco P; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., de Jesus RG; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Gössling G; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil., Soares A; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro Paulista de Oncologia (CPO) - Grupo Oncoclinicas, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil., Fay AP; Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Centro de Pesquisa em Oncologia (CPO) - Hospital São Lucas da PUCRS, Porto Alegre, Brazil.

Publikováno v: Clinical genitourinary cancer [Clin Genitourin Cancer] 2024 Oct; Vol. 22 (5), pp. 102174. Date of Electronic Publication: 2024 Jul 25.

Zobrazit plný text záznamu

Akademický článek

A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415).

Autor: Maluf FC; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil. Electronic address: maluffc@uol.com.br., Schutz FA; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Beneficência Portuguesa de São Paulo, São Paulo, Brazil., Cronemberger EH; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Centro Regional Integrado de Oncologia, Fortaleza, Brazil., Luz MA; Hospital Erasto Gaertner, Curitiba, Brazil., Martins SPS; Cepho-FMABC, Santo André, Brazil., Muniz DQB; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil., Bastos DA; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo, Brazil., Cárcano FM; Hospital de Câncer de Barretos, Barretos, Brazil., Smaletz O; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil., Soares A; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Hospital Israelita Albert Einstein, São Paulo, Brazil; Centro Paulista de Oncologia - Oncoclinicas, São Paulo, Brazil., Peixoto FA; Instituto COI de Educação, Pesquisa e Gestão em Saúde, Rio de Janeiro, Brazil., Gomes AJ; Liga Norte Riograndense Contra o Câncer, Natal, Brazil., Cruz FM; IBCC Oncologia - Centro Universitário São Camilo, São Paulo, Brazil., Franke FA; Oncosite - Centro de Pesquisa Clínica, Ijuí, Brazil., Herchenhorn D; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Oncologia D'OR/Instituto D'OR de Ensino e Pesquisa, Rio de Janeiro, Brazil., Dos Santos TM; Latin American Cooperative Oncology Group, Porto Alegre, Brazil., Fabricio VC; Janssen Pharmaceuticals, Argentina., Gidekel R; Janssen Pharmaceuticals, Argentina., Werutsky G; Latin American Cooperative Oncology Group, Porto Alegre, Brazil., de Jesus RG; Latin American Cooperative Oncology Group, Porto Alegre, Brazil., Souza VC; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; Oncologia D'OR, Salvador, Brazil., Fay AP; Latin American Cooperative Oncology Group, Porto Alegre, Brazil; PUCRS School of Medicine, Porto Alegre, Brazil; Grupo Oncoclínicas, Porto Alegre, Brazil.

Publikováno v: European journal of cancer (Oxford, England : 1990) [Eur J Cancer] 2021 Oct 13; Vol. 158, pp. 63-71. Date of Electronic Publication: 2021 Oct 13.

Zobrazit plný text záznamu

Clinical outcomes among ErbB2+MBC patients treated with lapatinib-capecitabine after trastuzumab progression: Role of early switch to lapatinib (TYCO study)

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_____10046::e7ae2d5381a09fe1cb3e60bd4f395bad
https://avesis.gazi.edu.tr/publication/details/ecc3f762-d986-4213-add1-d8b5cb4be4ca/oai

Zobrazit plný text záznamu

Akademický článek

Targeting FGFR for cancer therapy.

Autor: Zhang, Pei¹ (AUTHOR), Yue, Lin² (AUTHOR), Leng, QingQing¹ (AUTHOR), Chang, Chen¹ (AUTHOR), Gan, Cailing² (AUTHOR), Ye, Tinghong² (AUTHOR) yeth1309@scu.edu.cn, Cao, Dan¹ (AUTHOR) caodan@scu.edu.cn

Publikováno v: Journal of Hematology & Oncology. 6/3/2024, Vol. 17 Issue 1, p1-35. 35p.

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Evaluation of maintenance of the common androgen deprivation therapy with the new antiandrogen therapy in patients with castration-resistant prostate cancer: a systematic review.

Autor: Salgado, Carla Manzoni, Garcia-Perdomo, Herney Andrés, Reis, Leonardo O.

Publikováno v: International Urology & Nephrology; Jun2022, Vol. 54 Issue 6, p1187-1192, 6p

Zobrazit plný text záznamu

Akademický článek

81P Safety and effectiveness of apalutamide for the treatment of non-metastatic castration-resistant prostate cancer (nm-CRPC): Preliminary results from an open-label expanded access protocol (EAP).

Autor: Campos-Gomez, S.¹ (AUTHOR), Ochoa, J.C.² (AUTHOR), Cruz, F.³ (AUTHOR), Mota, A.⁴ (AUTHOR), Rios, M.A.J.⁵ (AUTHOR), Rinck, J.A.⁶ (AUTHOR), Bhaumik, A.⁷ (AUTHOR), Grings, M.⁸ (AUTHOR), Acerbi, A.⁸ (AUTHOR), Salomão, K.⁸ (AUTHOR), Fabricio, V.⁹ (AUTHOR), Gidekel, R.¹⁰ (AUTHOR)

Publikováno v: Annals of Oncology. 2021 Supplement 6, Vol. 32, pS1370-S1370. 1p.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání